Bal Pharma Confirms SEBI DP Reg. Compliance for Q1 FY27
Bal Pharma Limited confirms compliance with SEBI DP Regulations for the quarter ended June 30, 2026. Details of dematerialized/rematerialized securities were submitted to stock exchanges on time. Share certificates received for dematerialization were processed within 15 days.
This is a routine regulatory filing and does not have any immediate impact on the company's operations or stock performance.
The announcement is a routine compliance filing and does not contain any material financial or business developments, hence it is neutral.
Bal Pharma Limited has confirmed compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The company stated that details of securities dematerialized/rematerialized during the quarter ended June 30, 2026, have been furnished to all listed stock exchanges within the stipulated time.
Based on certificates received from their Registrar and Transfer agents, MUFG Intime India Private Limited, Bal Pharma also confirmed that any share certificates received for dematerialization have been duly verified, mutilated, and cancelled. The name of the depository has been substituted as the registered owner within 15 days of receipt.
The company has requested that this intimation be taken on record.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.